News

The biosimilar to aflibercept (Eylea) had already received approval in the EU and US.

RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells.

Risk factors vary in both short-term and long-term periods following Boston Type 1 keratoprosthesis surgery.

Arctic Vision has a commercial collaboration agreement with Santen Pharmaceutical Co., Ltd. to commercialize ARVN001 for the treatment of UME.

The researchers successfully tested the robot using enucleated pig eyes.

The imaging system is designed to enable secure, real-time remote monitoring around the clock, from virtually any location.

This research project, titled, “A Generalizable Deep Learning Platform for Unifying Quantification of Experimental Autoimmune Uveitis.”

Prevent Blindness will be sharing a variety of free educational resources to the public and professionals during the awareness week, which will be held February 24, 2025, through March 2, 2025.

The UK-based company will debut the tool, called Dr.Noon CVD, at two conferences in March

AVT06 is Alvotech’s proposed biosimilar to Eylea (aflibercept) 2mg.

The topline results from the COAST trial is anticipated in early Q2 of 2025.

PST-611, a first in class non-viral vectorized therapy expressing human transferrin, a highly potent iron regulator.

MonacoPro, the next evolution of Monaco from Optos, retains the powerful ultra-widefield SLO and spectral domain imaging while adding additional key product features.

OCU410 is a novel multifunctional modifier gene therapy candidate that targets multiple pathways associated with GA.

The submission deadline for both the 2025 Jenny Pomeroy Award for Excellence in Vision and Public Health and the sixth annual Rising Visionary Award is Monday, March 10, 2025, at noon ET.

The role of compounded anesthetic formulations in streamlining efficiency and elevating patient care.

The 15th annual meeting, taking from March 24–28 in Snowmass, Colorado, will deliver high-impact discussions on macular disease, artificial intelligence in ophthalmology, and breakthrough therapies—plus opportunities for networking on and off the slopes.

“Our current understanding of the pathophysiological basis of MacTel has led to the development of novel therapeutic approaches that may be able to break ground in this disease state.”

A recent study of AEYE-DS AI technology used in conjunction with the Topcon NW500 resulted in exceptional clinical diagnostic efficacy.

Working definition forwarded by NIH CVI Working Group

Donald Munoz has over 30 years of health care experience as a chief financial officer and an investment banker.

A look at the current state of AI in diabetic eye disease and where the future may take us.

How modern tools may lead to customized AMD treatment plans

Researchers screened for outcomes such as the presence of retinal diseases including age-related macular degeneration and retinal vein occlusion

David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial.